Jade Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
JBIO$15.60+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · December 31, · · December 31, · | |||||||
| · 2024 · 2023 | |||||||
| Assets · · · | |||||||
| Current assets: · · · | |||||||
| Cash and cash equivalents | | $33,751 | | $23,491 | | ||
| Short-term investments | | 44,872 | | 98,948 | | ||
| Prepaid expenses and other current assets | | 1,494 | | 1,793 | | ||
| Total current assets | | 80,117 | | 124,232 | | ||
| Property and equipment, net | | 6 | | 288 | | ||
| Operating lease right-of-use assets | | 209 | | 614 | | ||
| Other long-term assets | | — | | 2,284 | | ||
| Total assets | | $80,332 | | $127,418 | | ||
| | | | | | | | |
| Liabilities and Stockholders’ Equity | | | | | | | |
| | | | | | | | |
| Current liabilities: | | | | ||||
| Accounts payable | | $224 | | $2,396 | | ||
| Accrued and other current liabilities | | 3,187 | | 14,821 | | ||
| Operating lease liabilities | | 417 | | 420 | | ||
| Total current liabilities | | 3,828 | | 17,637 | | ||
| Operating lease liabilities, net of current portion | | — | | 255 | | ||
| Other liabilities | | 70 | | 70 | | ||
| Total liabilities | | 3,898 | | 17,962 | | ||
| | | | | | | | |
| Commitments and contingencies (Note 5) | | | | ||||
| Stockholders’ equity: | | | | ||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | | | — | | | — | |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; 28,985,019 and 27,762,703 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | | 3 | | 3 | | ||
| Additional paid-in capital | | 309,378 | | 272,640 | | ||
| Accumulated other comprehensive gain | | 105 | | 237 | | ||
| Accumulated deficit | | (233,052) | | (163,424) | | ||
| Total stockholders’ equity | | 76,434 | | 109,456 | | ||
| Total liabilities and stockholders’ equity | | $80,332 | | $127,418 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.